Herein, we report on the complimentary interactions of a rationally designed and dual targeted BsAb (CD47 x PD1), HX-009, which appears to exhibit superior activity over the monotherapies in various preclinical models of B- and T-cell lymphomas. The gene discussed is CD47; the disease is T-cell non-Hodgkin lymphoma.